Edwards Lifesciences Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Results

Core Insights - Edwards Lifesciences Corporation reported better-than-expected second-quarter financial results, with adjusted earnings of 67 cents per share, surpassing market estimates of 62 cents per share [1] - Quarterly sales reached $1.532 billion, exceeding expectations of $1.488 billion [1] - The company affirmed FY2025 adjusted EPS guidance of $2.40-$2.50 and raised FY2025 sales guidance from $5.70 billion-$6.10 billion to $5.90 billion-$6.10 billion [1] Financial Performance - The CEO highlighted strong second-quarter results with double-digit sales growth, attributing confidence in the full-year outlook to better-than-expected first-half performance and various catalysts across the portfolio [2] - Edwards Lifesciences shares increased by 5.1%, trading at $79.51 following the earnings announcement [2] Analyst Ratings and Price Targets - Baird analyst David Rescott maintained a Neutral rating and raised the price target from $78 to $79 [5] - Deutsche Bank analyst Pito Chickering maintained a Buy rating and increased the price target from $85 to $94 [5] - Evercore ISI Group analyst Vijay Kumar maintained an In-Line rating and raised the price target from $77 to $80 [5]